{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:41:52Z","timestamp":1750524112106,"version":"3.41.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05307-x","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T20:07:21Z","timestamp":1747858041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A response of rituximab plus lenalidomide therapy in patients with post-transplant lymphoproliferative disease and methotrexate-related lymphoproliferative disorder in the central nervous system: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Hanguo","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"4","key":"5307_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.24834","volume":"116","author":"R Cavaliere","year":"2010","unstructured":"Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group report. Cancer. 2010;116(4):863\u201370.","journal-title":"Cancer"},{"issue":"6","key":"5307_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","volume":"28","author":"AM Evens","year":"2010","unstructured":"Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038\u201346.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5307_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.transproceed.2004.12.130","volume":"37","author":"JF Buell","year":"2005","unstructured":"Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37(2):954\u20135.","journal-title":"Transplant Proc"},{"issue":"10","key":"5307_CR4","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/ajt.13324","volume":"15","author":"MR Luskin","year":"2015","unstructured":"Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015;15(10):2665\u201373.","journal-title":"Am J Transplant"},{"issue":"4","key":"5307_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molu\u00e7on-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020. Ann Oncol. 2019;30(4):621\u20138.","journal-title":"Ann Oncol"},{"issue":"31","key":"5307_CR6","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","volume":"25","author":"B Maecker","year":"2007","unstructured":"Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;25(31):4902\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5307_CR7","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-021-04548-2","volume":"100","author":"H Zimmermann","year":"2021","unstructured":"Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RM, et al. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Ann Hematol. 2021;100(8):2043\u201350.","journal-title":"Ann Hematol"},{"issue":"6","key":"5307_CR8","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/ajt.12211","volume":"13","author":"AM Evens","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13(6):1512\u201322.","journal-title":"Am J Transplant"},{"key":"5307_CR9","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2147\/CCID.S419534","volume":"16","author":"C Kositkuljorn","year":"2023","unstructured":"Kositkuljorn C, Rutnin S, Rattananukrom T, Puavilai T, Khiankaew B, Boonsakan P, et al. Cutaneous methotrexate-related Epstein-Barr virus-positive diffuse large B-cell lymphoma in a patient with granulomatous cutaneous T-cell lymphoma: a case report and literature review. Clin Cosmet Investig Dermatol. 2023;16:2229\u201335.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"22","key":"5307_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/jnci\/djh313","volume":"96","author":"WH Feng","year":"2004","unstructured":"Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22):1691\u2013702.","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"5307_CR11","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood.2023020075","volume":"142","author":"JE Amengual","year":"2023","unstructured":"Amengual JE, Pro B. How I treat posttransplant lymphoproliferative disorder. Blood. 2023;142(17):1426\u201337.","journal-title":"Blood"},{"issue":"4","key":"5307_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1399-3046.2006.00497.x","volume":"10","author":"AZ Traum","year":"2006","unstructured":"Traum AZ, Rodig NM, Pilichowska ME, Somers MJ. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients. Pediatr Transplant. 2006;10(4):505\u201312.","journal-title":"Pediatr Transplant"},{"issue":"3","key":"5307_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11060-010-0425-0","volume":"103","author":"A Patrick","year":"2011","unstructured":"Patrick A, Wee A, Hedderman A, Wilson D, Weiss J, Govani M. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neurooncol. 2011;103(3):739\u201343.","journal-title":"J Neurooncol"},{"issue":"9","key":"5307_CR14","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/13543784.2016.1208170","volume":"25","author":"S Garciaz","year":"2016","unstructured":"Garciaz S, Coso D, Schiano de Colella JM, Bouabdallah R. Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2016;25(9):1103\u201316.","journal-title":"Expert Opin Investig Drugs"},{"issue":"25","key":"5307_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803\u201311.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5307_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21468","volume":"84","author":"L Zhang","year":"2009","unstructured":"Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84(9):553\u20139.","journal-title":"Am J Hematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05307-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T20:07:21Z","timestamp":1747858041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05307-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5307"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05307-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of these cases was approved by the Ethics Committee of Guangdong Provincial People\u2019s Hospital, and written informed consent was obtained from the patients for the publication of their cases, including radiographic and pathological images. The ethics approval number was KY2025-100-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this manuscript have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}